LELaura Elst

Laura Elst

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Laura Elst has a total of 63 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Preexisting Immunity and hrHPV Status Determine Immunotherapy Response in Advanced Penile Cancer: Biomarkers and Overall Survival in the PERICLES Trial

    by Tynisha S. Rafael, Alberto Gil-Jimenez, Laura Elst, Hielke M. de Vries, Iris M. Seignette, Elise Bekers, Marta Lopez-Yurda, Dennis Peters, Marja Nieuwland, Erik Hooijberg, et al.

    Penile squamous cell carcinoma (PeSCC) is a rare malignancy with limited treatment options in advanced stages. The phase II PERICLES trial (NCT03686332) investigated atezolizumab with or without radiotherapy (RT) in advanced penile cancer. Here, we report mature overall survival (OS) and updated progression-free survival (PFS) outcomes and an in-depth biomarker analysis. Patients were treated with atezolizumab monotherapy (n = 12) or atezolizumab in combination with RT (n = 20, 33 fractions of 1.5–1.8 Gy) for locoregional disease control. Comprehensive analysis of baseline tumor tissue (n = 28/31) was performed using bulk RNA sequencing, immunohistochemistry, and multiplex immunofluorescence. Additionally, spatial transcriptomics (n = 9) was conducted to further explore functionality and (co-)localization of immune cell subsets. With extended follow-up (median: 38 months), landmark 2-year OS and PFS in the full study cohort was 18.8% [95% confidence interval (CI), 9.1–38.6] and 12.5% (95% CI, 5–31.3), respectively. High-risk human papillomavirus (hrHPV)-positive tumors were enriched for IFNγ and IFNα signatures, potentially explaining the improved PFS and OS observed in this subgroup. Both stromal CD68+ myeloid cell density and intratumoral CD8+PD-1+ T-cell density were associated with nonprogression at 1 year. Increased intratumoral CD8+PD-1+ T-cell density was also associated with improved PFS and OS, with consistent findings in the hrHPV-positive subgroup. Spatial transcriptomics identified these CD8+ T cells as tissue-resident cytotoxic effector cells coexpressing checkpoint molecules (LAG3 and TIGIT), chemokines (CCL4 and CXCL13), and cytotoxic molecules (PRF1 and GZMB). Interrogation of the penile cancer immune microenvironment highlights CD8+PD-1+ T cells as candidate biomarkers in relation to clinical benefit from immune checkpoint blockade in advanced PeSCC.

  • Local recurrence after glans‐sparing surgery: no impact on penile cancer‐specific survival

    by Laura Elst, Eduard Roussel, Marija Miletic, Hielke‐Martijn De Vries, Rick Verdijk, Sylvia Yan, Hussain Alnajjar, Davide Perri, Aishwarya Kaur, Richard Barry Sirard, et al.

    Objectives: To assess local recurrence (LR) and its impact on cancer‐specific survival (CSS) in an international multicentric homogeneous cohort of lower‐risk patients with penile squamous cell carcinoma (PSCC) that underwent glans‐sparing surgery (GSS). Patients and Methods: We retrospectively studied patients with PSCC treated with circumcision, wide local excision, glans resurfacing, partial glansectomy and laser ablation, collectively defined as GSS. To understand whether LR itself impacts CSS, patients with lymphatic or systemic disease prior or concurrent with LR were excluded. Predictors of LR and its impact on CSS were assessed using Cox proportional hazard regression and Kaplan–Meier survival analysis, respectively. Results: Across 15 institutions, 550 patients were included. The majority had pathological T1 stage (79%) tumours, reflecting the selection of less invasive tumours for GSS. At a median (interquartile range) follow‐up of 41 (23–63) months, 162 (29%) patients experienced LR. LR did not affect cancer‐specific mortality and 5‐year CSS remained at 99%. Three patients died from penile cancer, none of whom showed a LR during their disease course. The presence of penile intraepithelial neoplasia in the surgical margin was an independent predictor of LR (hazard ratio 2.28, P = 0.02), even after adjusting for additional treatments. Conclusion: Patients undergoing GSS for PSCC demonstrate excellent survival outcomes, despite LR in 29% of men. These findings support the use of GSS as a safe and effective treatment option for patients committed to adequate follow‐up.


  • The prognostic role of HPV status in penile squamous cell carcinoma: a systematic review and meta-analysis

    by Kaat Vandermaesen, Laura Elst, Claire Defraigne, Laura Langhendries, Yuhong Yuan, Maarten Albersen, Thomas Van Den Broeck

    Penile squamous cell carcinoma (PSCC) is a rare but aggressive malignancy that can present as either Human papillomavirus (HPV)-associated or HPV-independent. Currently, there is no consensus on the prognostic value of HPV status in PSCC or its role in guiding treatment strategies. Therefore, in this systematic review and meta-analysis we aim to assess the impact of different methods of determining HPV status on cancer specific survival (CSS) and overall survival (OS) in patients with PSCC. Databases including MEDLINE, Embase, and Cochrane Central Register of Controlled Trials were systematically searched between 1980 and February 2025. Studies were eligible if they assessed HPV status using any method in PSCC patients and reported CSS or OS with a minimum follow-up of two years. Case reports, narrative reviews, expert opinions, and studies reporting less than 50 participants were excluded. Quality of included studies was assessed using the QUIPS tool. A total of 31 studies, published between 2001 and 2024, met the inclusion criteria, all of which were of retrospective design. High risk of bias (RoB) was noted for study attrition, prognostic factor measurement, and study confounding. Sample sizes ranged from 57 to 611 participants (median: 152 participants). HPV-status was assessed through DNA testing in 19 studies and 10 studies used p16 immunohistochemistry (IHC) as a surrogate marker of HPV-driven carcinogenesis. Four studies used both HPV DNA measurements and p16 IHC staining and two articles determined HPV status based on histological subtyping. Median follow-up was 49.9 months (range: 27-107.9 months). We identified 23 studies that reported sufficient data for inclusion in a meta-analysis, encompassing a total of 5291 men with various stages of PSCC. Of these, 1946 (36.8%) had HPV-associated disease. Positive p16 status was associated with improved CSS (HR = 0.40, 95% CI [0.20, 0.80], p = 0.009) and OS (HR = 0.49, 95% CI [0.29, 0.85], p = 0.01) in a pooled cohort of 1266 and 1189 patients respectively. HPV DNA positivity was associated with improved CSS (HR = 0.54, 95% CI [0.35, 0.83], p = 0.005), but not with OS (HR = 0.86 95% CI [0.70, 1.07], p = 0.17). In conclusion, p16 and HPV DNA positivity are associated with improved CSS in patients with PSCC. Positive p16 status was related to better OS, while HPV status based on DNA measurements was not. These findings underscore the prognostic value of p16 and HPV status.


  • Emerging Advances in the Molecular Landscape of Penile Cancer and Their Implications for Precision Medicine

    by Laura Elst, Kaat Vandermaesen, Maarten Albersen

    Opinion statement Penile cancer is a rare but aggressive malignancy, characterized by early lymphatic spread which is the most critical prognostic factor. Treatment options for patients with locally advanced and metastatic disease are limited, primarily relying on cisplatin-based chemotherapy, which is characterized by high toxicity and early resistance. In recent years, there has been a growing interest on translational research exploring the tumor microenvironment, enabling the identification of novel potential therapeutic targets. Emerging preclinical evidence supports the use of immune checkpoint inhibitors, antibody–drug conjugates and novel exploratory therapies targeting myeloid-derived suppressor cells and tumor associated macrophages, as well as their combinations. However, robust phase III trials investigating such therapies are currently lacking. A deeper understanding of the penile cancer immune landscape and the role of specific mutations in carcinogenesis, might lead to the development of novel combination strategies to overcome cisplatin resistance and disease progression, and to a better selection of patients for inclusion in future clinical trials.


  • Penile intraepithelial neoplasia incidence, clinical classification, microenvironment and implications for imiquimod treatment

    by Ofir Avitan, Tynisha Rafael, Manon Vreeburg, Laura Elst, Elise M. Bekers, Maarten Albersen, Ekaterina S. Jordanova, Oscar Brouwer

    Objectives: To provide an outline of the existing data on penile intraepithelial neoplasia (PeIN), as well as a narrative review on imiquimod (IQ; a toll‐like receptor 7 agonist) treatment and immune microenvironment markers that may predict response to treatment. Methods: A narrative review of the literature from 2000 to the present was conducted on PubMed, and we describe the most relevant data and cross references. Results: The incidence of PeIN is increasing. Local therapy with IQ may offer an easy applicable treatment with complete response rates of up to 63% but can be associated with considerable side‐effects. There is no conclusive data on the optimal treatment schedule for PeIN, but evaluation of treatment results for other human papillomavirus‐related pre‐malignancies suggest three times a week for a duration up to 16 weeks. There are no published studies concerning the PeIN immune microenvironment. However, findings from the few studies on penile cancer and pre‐cancerous vulvar and cervical lesions imply that specific immune cell subpopulations can serve as future predictors for successful immunomodulation treatments such as IQ. Conclusions: Overall, limited data are available on IQ treatment for PeIN and no published data exists on the PeIN immune microenvironment. Further translational studies are warranted to gain more understanding on the pathophysiology of PeIN and potential predictors of progression and of response to topical treatments.


  • Open Access

    International case series of metastasis to penis

    by Irini Youssef, Laura Elst, Nick Watkin, Hielke Martijn de Vries, Oscar Brouwer, Chris Protzel, Benjamin Ayres, Maarten Albersen, Philippe E. Spiess, Peter A. S. Johnstone

    Penile metastases are rare, with about 400 reported via case reports or small series. Under such circumstances coherent data about their behaviour may not be possible given vagaries of publication. For instance, one published meta‐analysis has proposed that malignant priapism contributes to worse survival, but this may be due to selection bias in published reports. We sought to evaluate clinical characteristics associated with survival in an international cohort of patients with metastases to the penis treated in major genitourinary cancer programmes.